跳至主要内容
临床试验/EUCTR2011-002532-12-IT
EUCTR2011-002532-12-IT进行中(未招募)1 期

Catheter Ablation Versus Antiarrhythmic Drug Therapy for Atrial Fibrillation Trial (CABANA) - CABANA

MAYO CLINIC0 个研究点目标入组 3,000 人开始时间: 2012年4月12日最近更新:
适应症

试验速览

阶段
1 期
状态
进行中(未招募)
发起方
MAYO CLINIC
入组人数
3,000

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • 1. Have documented AF episodes =1 hour in duration; with =2 episodes over 4 months with electrocardiographic documentation of 1 episode orat least 1 episode of AF lasting more than 1 week 2. Warrant active therapy beyond simple ongoing observation. 3. Be eligible for catheter ablation and= 2 sequential rhytmn control and/or =3 rate control. 4. Be =65 years of age, or <65 years with one or more of the following risk factors of stroke: Hypertension defined as BP >140/90 mmHg Diabetes defined as a fasting glucose=126 mg/dl, Congestive heart failure (including systolic or diastolic heart failure), prior stroke or TIA, LA size =5.0 cm (or volume index = 40cc/m2), or EF =35. Subjects <65 yrs of age whose only risk factor is hypertension must have a second risk factor or LV hypertrophy to quality. 5. Have the capacity to understand and sign an Informed concent form. 6. Be =18 years of age.
  • Are the trial subjects under 18? no
  • Number of subjects for this age range: 0
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 40
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range 24

排除标准

  • 1. Lone AF in the absence of risk factors for stroke in patients <65 years of age 2. Patients who in the opinion of the managing clinician should not yet receive any therapy for AF 3. Patients who have failed =2 membrane active anti-arrhythmic drugs at a therapeutic dose due to inefficacy or side effects 4. More than one week of amiodarone treatment in the past 3 months 5. An efficacy failure of full dose amiodarone treatment =12 weeks duration at any time 6. Reversible causes of AF including thyroid disorders, acute alcohol intoxication, recent major surgical procedures, or trauma 7. Recent cardiac events including MI, PCI, or valve or bypass surgery in the preceding 3 months 8. Hypertrophic obstructive cardiomyopathy 9. Class IV angina or Class IV CHF (including past or planned heart transplantation) 10. Other mandated anti-arrhythmic drug therapy 11. Heritable arrhythmias or increased risk for torsade de pointes with class I or III drugs 12. Prior LA catheter ablation with the intention of treating AF 13. Prior surgical interventions for AF such as the MAZE procedure 14. Prior AV nodal ablation 15. Patients with other arrhythmias requiring ablative therapy 16. Contraindication to warfarin anti-coagulation 17. Renal failure requiring dialys 18. Medical conditions limiting expected survival to <1 year 19. Women of childbearing potential (unless post-menopausal or surgically sterile) 20. Participation in any other clinical mortality trial 21. Unable to give informed consent

研究者

发起方
MAYO CLINIC

相似试验

进行中(未招募)
不适用
Catheter Ablation Versus Antiarrhythmic Drug Therapy for Atrial Fibrillation TrialAtrial fibrillation
EUCTR2011-002532-12-CZMayo Clinic3,000
进行中(未招募)
1 期
Catheter Ablation Versus Antiarrhythmic Drug Therapy for Atrial Fibrillation TrialMedDRA version: 19.0Level: PTClassification code 10003658Term: Atrial fibrillationSystem Organ Class: 10007541 - Cardiac disordersAtrial fibrillation
EUCTR2011-002532-12-DEMayo Clinic2,200
招募中
不适用
Catheter Ablation versus Medical Therapy for Ventricular Tachycardia: A Randomised TrialStructural Heart DiseaseCardiovascular - Other cardiovascular diseasesIschemic cardiomyopathyArrhythmogenic right ventricular cardiomyopathyVentricular TachycardiaSarcoidosisHypertrophic CardiomyopathyDilated Cardiomyopathy
ACTRN12620000045910Western Sydney Local Health District162
已完成
不适用
Catheter Cryoablation versus Antiarrhythmic Drug as First-Line Therapy of Paroxysmal Atrial FibrillatioCryo ablation10007521Atrial Fibrillation
NL-OMON42900Medtronic B.V.26
进行中(未招募)
1 期
Protection offered by N-Acetylcysteine against radiation induced cellular damage in patients undergoing ablation procedures because of cardiac arrhythmia.Patients with Cardiac Arrhythmia who undergo catheter ablation procedures guided by x-Ray imagingMedDRA version: 23.1Level: LLTClassification code 10007518Term: Cardiac arrhythmiaSystem Organ Class: 100000004849
EUCTR2019-001995-12-ITCENTRO CARDIOLOGICO SPA FONDAZIONE MONZINO550